Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia-reperfusion model.
OBJECTIVE
The aim of this study was to investigate the efficacy of sodium nitroprusside in the reduction of the intestinal ischemia-reperfusion injury as a nitric oxide donor after intraperitoneal administration.


METHODS
The histopathological examinations and tissue malonyldialdehyde levels of 35 Wistar albino rats that were subjected to ischemia-reperfusion, were performed in 5 groups. The groups include Control, Ischemia -reperfusion, Sodium nitroprusside, NG-Nitro-L-Arginine Methyl Ester (L-NAME) and Sodium nitroprusside+L-NAME. Each rat was subjected to ischemia for 40 minutes and reperfusion for 30 minutes, except the control group. The medications were done intraperitoneally as saline 4 ml/kg, Sodium nitroprusside 5 mg/kg, L-NAME 10 mg/kg just before reperfusions.


RESULTS
Significant tissue injury in histological sections and an increase in tissue levels of Malonyldialdehyde was detected in the I/R group. The efficacy of intraperitoneal administration of Sodium nitroprusside in both Sodium nitroprusside alone and Sodium nitroprusside+L-NAME groups was found statistically significant for the reducing of injury scores (p<0.05). The difference between the Ischemia/reperfusion and Sodium nitroprusside groups was found statistically significant as in the Ischemia/reperfusion and Sodium nitroprusside+L-NAME groups due to the tissue Malonyldialdehyde levels (p<0.05). There was no statistical difference between Ischemia/reperfusion and L-NAME groups.


CONCLUSIONS
Ischemia/reperfusion induced injury might be reduced by the intraperitoneal administration of Sodium nitroprusside, even in the presence of L-NAME, in the rat intestinal model.
Emre
Ali
A
General Surgery, Zonguldak Karaelmas University, Turkey. auemre@gmail.com
Bayram
Orhan
O
Salman
Bulent
B
Ercan
Sevim
S
Anadol
Ziya
Z
Akin
Okhan
O
D000818:Animals; D004195:Disease Models, Animal; D007422:Intestines / Q000098:blood supply* / Q000473:pathology; D007511:Ischemia / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy / Q000473:pathology*
D020030:Nitric Oxide Donors; D009599:Nitroprusside; D008315:Malondialdehyde; D019331:NG-Nitroarginine Methyl Ester